Page 794 - Read Online

Page 14 of 16 Zanetto et al. Hepatoma Res 2018;4:70 I http://dx.doi.org/10.20517/2394-5079.2018.102

patients with advanced liver disease. Gastroenterology 2015;149:649-59.
24. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated
cirrhosis. N Engl J Med 2015;373:2618-28.
25. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl
J Med 2015;373:2599-607.
26. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N
Engl J Med 2014;370:1594-603.
27. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med
2015;373:2608-17.
28. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J
Med 2014;370:1983-92.
29. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients
without treatment options. N Engl J Med 2013;368:1867-77.
30. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J
Med 2014;371:2375-82.
31. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N
Engl J Med 2013;368:1878-87.
32. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with
cirrhosis. N Engl J Med 2014;370:1973-82.
33. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, et al. Exploratory study of oral combination antiviral therapy for hepatitis C.
N Engl J Med 2013;368:45-53.
34. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, et al. Daclatasvir plus sofosbuvir for previously treated or
untreated chronic HCV infection. N Engl J Med 2014;370:211-21.
35. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related
HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
36. Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, et al. Hepatic venous pressure gradient predicts development of hepatocellular
carcinoma independently of severity of cirrhosis. J Hepatol 2009;50:923-8.
37. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related
cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
38. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, et al. Incidence and predictors of hepatocellular carcinoma in patients with
cirrhosis. Clin Gastroenterol Hepatol 2007;5:938-45.
39. Buonfiglioli F, Conte F, Andreone P, Crespi C, Foschi FG, et al. Development of hepatocellular carcinoma in HCV cirrhotic patients treated
with direct acting antivirals. J Hepatol 2016;64:S125.
40. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, et al. Outcomes after successful direct-acting antiviral therapy for patients
with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-7.
41. Muir AJ, Buti M, Nahass R, Agarwal K, Gane EJ, et al. Long-term follow-up of patients with chronic HCV infection and compensated or
decompensated cirrhosis following treatment with sofosbuvir-based regimens. Hepatology (Baltimore, Md.) 2016;64:437A-8A.
42. Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, et al. Newly diagnosed hepatocellular carcinoma in patients
with advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol. 2018;69(2):345-52.
43. Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, et al. The risks of hepatocellular carcinoma development after HCV eradication are
similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One 2017;12:e0182710.
44. Ji D, Wang C, Shao Q, Li F, Wu V, et al. No increase in the occurrence rate of hepatocellular carcinoma in Chinese treated by direct-acting
antivirals compared to interferon after eradication of hepatitis c virus: a long-term follow-up. J Hepatol 2017;66:S23.
45. Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, et al. Sustained virologic response by direct antiviral agents reduces the
incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol 2017;89:476-83.
46. Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence
of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 2017;67:933-9.
47. Affronti A, Ju M, Catt J, Rosenberg WM, Macdonald D. Successful hepatitis C treatment in advanced cirrhosis with DAA reduces HCC
incidence. Hepatology 2016;64:475A.
48. Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay JP, et al. The risk of early occurrence and recurrence of hepatocellular
carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: a Belgian experience. J
Viral Hepat 2017;24:976-81.
49. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J
Hepatol 2017; doi: 10.1016/j.jhep.2017.08.030.
50. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients
with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 2016;65:856-8.
51. Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, et al. High incidence of hepatocellular carcinoma following successful
interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol 2016;65:1070-1.
52. Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, et al. Direct-acting antiviral treatment for hepatitis C virus infection and risk
of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther 2018;47:1278-87.
53. Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis
C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology 2018;67:2244-53.
54. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation